Accurate measurement of IGF-I is a complex issue, as the results depend on the type of analytical method. This variability can be attributed to differences in the calibration material, the epitope specificity of the different antibodies, and interference with IGF-I binding proteins (1, 5) . A universal calibrator is crucial for assay standardization. A recent consensus statement on the evaluation and standardization of IGF-I assays recommends the IS 02/254 World Health Organization reference standard, a .97%-pure recombinant standard that has been well characterized by the National Institute for Biological Standards and Control (6) .
Even if they give different results, one would expect two different IGF-I assays to classify a given patient in the same way (high, normal, or low values). However, even when using kits that are calibrated against the same international standard, and the same method to remove IGF-I binding proteins, patient classification in terms of IGF-I categories remains variable (7) (8) (9) (10) . We suspected that a potential reason for these discrepancies was the use of different reference values. Indeed, it is difficult to establish IGF-I normative data, as they depend on the choice of a healthy reference population (6, 11, 12) . Although IGF-I values depend on many factors, such as sex, age, nutritional status, treatments (especially hormonal medications), diabetes, and renal and hepatic failure, normative data used for the different IGF-I kits were not obtained in the same, apparently healthy, population. Furthermore, the distribution of IGF-I levels in healthy populations is nonGaussian, and transformations are thus necessary to obtain normal distributions and to calculate standard deviation scores (SDSs). This prompted us to conduct the VARIETE study (VAleurs de Référence de l'IGF-I Et Transformation En z score) to establish normative reference values for six IGF-I immunoassays in the same healthy adult population, using the same statistical method to calculate SDSs (13) . We postulated that this would help to longitudinally assess disease control in a given patient using the IGF-I SDSs, even if IGF-I was measured with more than one assay during follow-up.
In the current study, we measured IGF-I with the same six kits in 102 patients with acromegaly or GH deficiency, and used the age-and sex-adjusted normative reference values from the VARIETE study to compare the raw data and SDS values obtained for each patient with each assay. We thus determined whether the patients' classifications were concordant.
Subjects and Methods

Study population
One hundred two patients (57 men and 45 women) belonging to the cohort of Service d'Endocrinologie et des Maladies de la Reproduction of Hôpitaux Universitaires ParisSud (Bicetre Hospital), Le Kremlin-Bicêtre, France, were enrolled in the study between December 2013 and March 2014. Fifty-six patients had acromegaly. Thirty-two patients had a blood sample taken at diagnosis (n = 11) or after incomplete surgery and before initiation of medical treatment (n = 21), and 24 patients were sampled during follow-up on medical treatment (cabergoline alone, n = 1; somatostatin analog alone, n = 10; pegvisomant alone, n = 9; somatostatin analog and cabergoline, n = 3; and somatostatin analog and pegvisomant, n = 1) but with variable disease control (because of treatment modification, reinforcement, or titration, or because they were resistant to medical treatment). Diagnosis of acromegaly was based on clinical criteria, unsuppressed GH in the oral glucose tolerance test, IGF-I elevation, and imaging or histologic proof of a somatotroph pituitary adenoma after surgery (2, 14, 15) . Fourteen patients had GHD, either confirmed by a serum GH peak less than 5 mg/L after the insulin tolerance test (six patients) or strongly suggested by deficiencies in at least three other pituitary functions (4) . Another 32 patients had other pituitary or endocrine disorders and were tested for suspected acromegaly or GHD. The patients' characteristics are summarized in Table 1 . Each patient underwent a clinical examination, had a personal medical history obtained and was sampled at 8:00 AM after an overnight fast. Six patients had serial IGF-I measurements with three to six IGF-I assays (at diagnosis, after pituitary surgery, and during medical treatment with somatostatin analogs). All the patients gave their written informed consent to participate in the study, which was approved by the Paris-Sud Ethics committee.
In each patient, IGF-I values were measured with the six assay kits (see later) used in the recently published VARIETE study (13) . The main characteristics of the assays are shown in Supplemental Table 1 .
Normative reference range
The normative reference data that we used to classify patients as having "normal," "high," or "low" IGF-I levels were obtained in the VARIETE study (13) . In brief, this study was a cross-sectional, multicenter (24 centers), nationwide French cohort study (ClinicalTrials.gov no. NCT01831648) designed to develop reference normative sex-and age-adjusted IGF-I data for the adult general population for each of the different assay techniques widely used in everyday clinical practice in France. The objective of this study was also to propose formulas for calculating IGF-I SDSs, taking into account the non-normal distribution of IGF-I levels in the healthy population. The study population consisted of 911 subjects (470 males), comprising 101, 118, 99, 98, 103, 102, 108, 97, and 85 subjects in the 18-to 20-, 21-to 23-, 24-to 26-, 27-to 29-, 30-to 39-, 40-to 49-, 50-to 59-, 60-to 69-, and 70-to 89-year age groups, respectively. Serum IGF-I was measured with the following six assay kits: iSYS (ImmunoDiagnostic Systems, Boldon, United Kingdom), Liaison XL (Diasorin, Saluggia, Italy), Immulite 2000 (Siemens, Erlangen, Germany), IGF-I RIACT (CIS BIO, Gif sur Yvette, France), Mediagnost ELISA, and Mediagnost RIA (Mediagnost, Reutlingen, Germany). IGF-I values were then matched in 3-year groups between 18 and 30 years of age and 10-year groups between 30 and 90 years, and mean and median values as well as the 2.5th and 97.5th percentiles were calculated. For each sex and age category, the distribution of measurements was normalized by means of sex-and age-specific Cox-Box power transformation to calculate SDSs. As men and women had significantly different IGF-I levels, curves were constructed separately using the LMS method.
The VARIETE study thus established age-and sex-specific adult normative data for the six commercial IGF-I assays, including the range of values from the 2.5th to the 97.5th percentile in mass units, and provided a formula for calculating SDSs. A calculator available online (http://ticemed_sa.upmc.fr/ sd_score/) or as an app (IGF-I_SD_score) downloadable for Android from Google Play and for iOS from the Apple Store (free of charge) yields individual IGF-I SDSs after entering the name of the assay, the individual's IGF-I value obtained with the assay, and the sex and age of the individual.
Statistics
Data were analyzed with Statistical Analysis System software (version 9.4; SAS Institute, Cary, NC). We used scatter plots and Bland-Altman plots to assess pairwise concordance between assays, both for IGF-I raw values and SDS values. We classified the IGF-I results in three categories, high (SDS .+1.96), normal (SDS between -1.96 and +1.96), and low (SDS ,-2), and evaluated pairwise agreement by means of the linearly weighted k coefficient.
To interpret the k coefficient, we used the Fermanian scale 
Results
Variability of individual IGF-I SDS values according to the IGF-I assay
Variability between each individual's IGF-I SDS obtained with each of the six immunoassays is illustrated in Fig. 1 for the 57 male patients and the 45 female patients. Many patients were inconsistently classified, particularly when IGF-I values were close to the reference range.
In six prospectively followed patients with acromegaly, IGF-I was measured on three occasions (at diagnosis, after surgery, and at follow-up, generally under medical treatment) with between three and six of the IGF-I assays (Fig. 2) . With the exception of one patient in whom two of the three assays used at diagnosis gave a high IGF-I SDS, IGF-I SDSs were generally concordant in the elevated levels. In three out of six patients with borderline IGF-I SDS after surgery, IGF-I SDS was either normal using some assays, suggesting that the patient was cured, or moderately elevated using other assays, suggesting that the patient had persistent active disease. At follow-up under treatment, when IGF-I SDS was borderline, some assays classified the patient as "controlled," although others gave a low SDS.
Percentages of patients classified as having normal, high, or low IGF-I levels in the different IGF-I assays
The percentages of patients classified as having high (.+1.96), normal (between -1.96 and +1.96), and low (,-1.96) SDS values are shown in Fig. 3 . The iSYS and Mediagnost RIA kits classified fewer patients as having "normal" levels (33% and 35%, respectively, vs 46% to 49% for the other assays) and, on the contrary, more patients as having "high" IGF-I values (54% and 51%, respectively, vs 30% to 39%). On the other hand, IGF-I RIACT and Liaison XL were more likely to classify the patients as having "low" IGF-I levels (20% and 23%, respectively, vs 13% to 16%).
Pairwise correlations between raw data and z scores obtained with the six IGF-I immunoassays
The results obtained with each IGF-I assay were compared with those obtained with each of the other five assays. Scatter plots and Bland-Altman plots based on raw values and SDSs for each pair of assays are shown in Supplemental Fig. 1 .
Two examples of interassay comparisons are shown in Fig. 4 . The results obtained with iSYS and Mediagnost RIA were in good overall agreement, with no significant bias on Bland-Altman plots [ Fig. 4(a-d)] . Indeed, the discrepancy around the mean difference (average difference) line was quite stable when the average value increased, without very wide limits of agreement, and with consistent variability across the graph. In contrast, the results obtained with Liaison XL and iSYS were not in good agreement, as the mean difference line was clearly different from zero and as iSYS tended to overestimate IGF-I values by comparison with Liaison XL, an effect that was accentuated as the average value increased, especially for raw data [ Fig. 4(e-h) ].
Pairwise assay concordances (weighted k coefficient) for categorized IGF-I SDS values are shown in Table 2 . The best concordance was found between iSYS and Mediagnost RIA, with a k coefficient of 0.81. Very good agreement was also observed between Immulite and Mediagnost ELISA (k coefficient, 0.77), Mediagnost Table 2) . When we limited the assessment of concordance to the group of patients with acromegaly (n = 56), the best pairwise agreement was again between iSYS and Mediagnost RIA, with a weighted k coefficient of 0.81, whereas the worst agreement was between Liaison XL and iSYS and between Immulite and Mediagnost ELISA (k coefficient, 0.41 for both).
Concordance between assays according to IGF-I SDS classes (high, normal, and low)
We analyzed concordance according to IGF-I SDS classes (high, .1.96; normal, between -1.96 and 1.96; 
Discussion
Our results show significant variability among six commercial immunoassays for the determination of individual IGF-I SDS values and IGF-I classification of 102 patients with various GH disorders, despite the use of normative reference intervals obtained, for each of the six assays, in the same, large, well-selected population of healthy French adults (13) , as recommended by the Consensus Group on the Standardization and Evaluation of GH and IGF-I Assays (6) .
Reliable normative reference intervals are necessary for the diagnosis of acromegaly and GHD, for the followup of patients with GH disorders, and for the detection of remission and recurrence of GH-related diseases. In 2011, a consensus statement on the standardization and evaluation of GH and IGF-I assays proposed the use of the international recombinant IGF-I calibration standard preparation 02/254 and emphasized the importance of antibody specificity, quality control analysis, and the elimination of interference with binding proteins. It also emphasized the importance of obtaining normative data based on a random selection of individuals from the background population, representing all age groups, after exclusion of individuals with poorly controlled diabetes or renal or hepatic failure or taking medications (such as estrogen) that could affect outcome.
Based on this consensus statement, Bidlingmaier et al. (18) published normative data for the iSYS IGF-I assay obtained in a cohort of 15,014 healthy subjects, while we recently proposed IGF-I reference intervals obtained with six widely used immunoassays in the same population of 911 healthy French adults aged from 18 to 92 years, as per the consensus recommendations (13) . The inclusion criteria were strict, with careful clinical evaluation, a medical history-taking that included ongoing treatments, and exclusion of subjects receiving steroid hormones. In addition, separate curves were constructed for each sex, in view of significantly different IGF-I levels between men and women. Normative data ranged between percentiles 2.5 and 97.5 and were reported in mass units and SDSs. Nevertheless, although we ensured the same preanalytical conditions for all six immunoassays, and although four of the six assays were calibrated against the same international reference standard 02/254, concordance across the assays remained variable, both for raw data and IGF-I SDSs (13).
To extend the results of our study of healthy individuals to the clinical setting, we created a group of patients of both sexes (57 males and 45 females) encompassing the whole spectrum of serum IGF-I levels, from very low (severe GHD) to very high (highly active acromegaly), representing the everyday practice of laboratories involved in IGF-I measurement. We therefore analyzed the concordance between the results obtained with each of the six assays in each of the 102 patients.
Pairwise agreement between the assays ranged from moderate to excellent. The best concordance was observed between iSYS and Mediagnost RIA. These two immunoassays, calibrated against the same international standard 02/254, classified fewer patients than the other four assays as "normal," and more patients as having "high" IGF-I serum levels. In the VARIETE study, the largest intercentile intervals and highest absolute values (in micrograms per liter) were obtained with Immulite and IGF-I RIACT, the two immunoassays calibrated against the old standard International Reference Preparation 87/518 (13) . However, when using SDSs in the present group of patients, instead of absolute mass values, these two immunoassays classified similar percentages of patients as having "normal" IGF-I levels as the Liaison XL assay and Mediagnost ELISA. Moreover, the three automated assays (Immulite, Liaison XL, and iSYS) did not show excellent pairwise concordance: The pairs Liaison XL/iSYS and Immulite/iSYS This lack of concordance between certain assays has already been reported (7-10): One possible explanation was that the populations used to establish normative data were different or that the quality of these normative data were suboptimal (too few patients studied, particularly in certain age ranges; bias; failure to select healthy subjects with regard to concurrent treatments or medical conditions interfering with IGF-I measurement; etc.) (5, 6, 11, 12, 19) . This is why we used the same large healthy population to establish normative data for the six immunoassays used here. Despite this, discordant results persisted between some assays, with some pairs being clearly more discordant than others.
Another possible explanation for the lack of concordance is a difference in the technical procedure (5, 6, 12, 19 ). In the current study, the preanalytic procedure was exactly the same, and only the analytic procedure therefore differed. As underlined in our study of healthy volunteers, in which we also found such discordances (13), the most plausible explanation lies in the capacity of the assay to remove insulinlike growth factor binding proteins and the specificity and performance of the antibody. This may be particularly true for high IGF-I values, which are usually associated with high levels of insulinlike growth factor binding protein 3.
These results confirm that, even when using normative values established in the same population of healthy subjects, IGF-I results obtained with different assays in a given individual, whether healthy (as in the VARIETE study) or having a GH-related disorder (as in the current study), are sometimes very different, potentially leading to patient misclassification.
It is crucial to understand the reasons behind differences in the results of commercial IGF-I immunoassays. Assays with similar characteristics must be used for the follow-up of a given patient. Assays that tend to overestimate or (20, 21) . Reference intervals obtained with LC-MS seem very similar to those obtained with immunoassays (22) . However, LC-MS is a time consuming and complex method that requires expensive machines and technical expertise to control the many variables that can influence the results (23) . Thus, despite their limitations, immunoassays will continue to be widely used, at least in the near future.
In conclusion, IGF-I levels obtained with six commercial IGF-I immunoassays widely used in clinical practice, and calculated IGF-I SDSs, were quite variable in patients with GH-related disorders, despite the use of normative reference intervals obtained in the same large, well-defined population of French healthy adults. It is not possible, according to the results of this study, to recommend one assay or the other. From a practical point of view, very high levels or very low levels of IGF-I are generally concordant, whatever the assay that is used, and classification of patients as having active acromegaly or severe GH deficiency is generally similar. On the contrary, when IGF-I levels are borderline, classification may differ from one assay to the other. This requires caution in interpretation of borderline IGF-I levels. In this context, we do not recommend to follow a patient and to take therapeutic decisions based on IGF-I SDSs calculated with one assay one day and another assay another day. On the contrary, a given patient should preferably be monitored with the same IGF-I assay.
